tirzepatide manufacturer eli lilly sues companies selling alternative versions of its weight loss drug Eli Lilly's tirzepatide scores again,

#Biosimilars #FDA #Healthcare To view or add a comment, sign in Medicare Part D Enrollment is here

En octubre del 2025 la FDA amplio la indicacin de simaglutida para la reduccin del riesgo de eventos cardiovasculares mayores (muerte cardiovular, infarto al miocardio no fatal, ataque vascular no fatal) en adultos con diabetes mellitus tipo 2 (no insulinodependiente) que tienen riesgo alto de desarrollar estos eventos

Additionally, GLP-1 RAs inhibit gallbladder and gastric emptying, as well as intestinal motility, thereby reducing energy intake

Aspirin is inexpensive, widely available, and supported by randomized evidence, but its bleeding risk limits universal use

There are no specific food restrictions, but it is beneficial to focus on a balanced, nutritious diet

Bring a list of all medications (including over-the-counter products and supplements), and note any recent changes to your health or lifestyle